Evolent Health, Inc $EVH Shares Purchased by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL raised its position in Evolent Health, Inc (NYSE:EVH) by 174.4% during the third quarter, HoldingsChannel reports. The firm owned 689,262 shares of the technology company’s stock after purchasing an additional 438,095 shares during the period. Tudor Investment Corp ET AL’s holdings in Evolent Health were worth $5,831,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EVH. Brighton Jones LLC acquired a new stake in shares of Evolent Health in the fourth quarter valued at about $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Evolent Health by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock valued at $1,217,000 after acquiring an additional 3,572 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Evolent Health by 162.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after acquiring an additional 1,754,520 shares during the last quarter. Caxton Associates LLP purchased a new position in Evolent Health in the 1st quarter worth approximately $252,000. Finally, Strs Ohio acquired a new position in shares of Evolent Health during the 1st quarter worth approximately $47,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Needham & Company LLC lowered their price objective on Evolent Health from $15.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Truist Financial lowered their price objective on Evolent Health from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $3.50 price target on shares of Evolent Health in a research note on Wednesday, February 25th. TD Cowen reiterated a “buy” rating on shares of Evolent Health in a report on Monday, March 2nd. Finally, UBS Group decreased their target price on shares of Evolent Health from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.04.

Evolent Health Stock Down 9.0%

Shares of EVH opened at $2.27 on Wednesday. The company’s 50-day simple moving average is $3.13 and its 200-day simple moving average is $4.99. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.31 and a current ratio of 1.31. Evolent Health, Inc has a 1 year low of $2.25 and a 1 year high of $12.06. The stock has a market capitalization of $252.86 million, a PE ratio of -0.44 and a beta of 0.24.

Evolent Health (NYSE:EVH) last announced its earnings results on Tuesday, February 24th. The technology company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The firm had revenue of $468.72 million for the quarter, compared to the consensus estimate of $468.48 million. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.49%. The firm’s revenue for the quarter was down 27.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.02) EPS. Analysts forecast that Evolent Health, Inc will post 0.08 earnings per share for the current fiscal year.

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.